Furthermore, the estimated 2856 patients with HER2-negative advanced G/GEJa in Spain who were eligible for 1L treatment with polychemotherapy in 2024 represent a substantial proportion of the total number of new cases of G/GEJ cancer in Spain in 2024 (6868 patients), underscoring this unmet need. This evidence concerns the gene ERBB2 and cancer.